Results 111 to 120 of about 386 (142)
Some of the next articles are maybe not open access.
Frontiers of rapid itch relief: a review of methylprednisolone aceponate
Journal of the European Academy of Dermatology and Venereology, 2012AbstractIn a paediatric population, the successful management of childhood atopic dermatitis (AD) should include the careful evaluation and selection of available therapies, based not only on demonstrated safety and tolerability in small children and infants, but also on their evidence‐based, anti‐pruritic benefits. Moreover, the speed of anti‐pruritic
L, García Ponte, U, Ebert
openaire +2 more sources
Methylprednisolone aceponate for atopic dermatitis
International Journal of Dermatology, 2017AbstractBackgroundThe 4th generation topical corticosteroids (TCS) have demonstrated a most favorablerisk–benefit ratio. Methylprednisolone aceponate (MPA) is a non‐halogenated corticosteroid with a methyl group at C6, which confers higher intrinsic activity.
openaire +2 more sources
Allergic contact dermatitis from 6α‐methylprednisolone aceponate and budesonide
Contact Dermatitis, 1998---
CORAZZA, Monica, VIRGILI, Anna
openaire +2 more sources
Systemic effects of topically applied methylprednisolone aceponate in healthy volunteers
Journal of the American Academy of Dermatology, 1993Many skin diseases respond to topical corticosteroid therapy. The first drug of this class, hydrocortisone, has been succeeded by ever more potent corticosteroids. However, these have a greater potential for systemic and local side effects. I, 2 Aseparation of clinical effects and epidermal thinning was first described with clobetasone butyrate.' which
A, Kecskés +4 more
openaire +2 more sources
Skin atrophogenic potential of methylprednisolone aceponate (MPA)
Journal of the European Academy of Dermatology and Venereology, 1994AbstractThe most prominent and most discussed local side effect of topical corticosteroids is the thinning of the skin. Therefore, the atrophogenic potential is an important indication of the quality of a new corticosteroid. Several studies have been conducted to investigate this parameter. In rats, the effect of breaking strength of the skin, the most
openaire +1 more source
European Journal of Clinical Pharmacology, 1992
Topical glucocorticosteroids are useful in the treatment of various skin diseases. Although many corticosteroids are available today, there is still a need for highly potent compounds with minimal adverse effects. Methylprednisolone aceponate (MPA) has recently been synthesized.
A, Kecskés +4 more
openaire +2 more sources
Topical glucocorticosteroids are useful in the treatment of various skin diseases. Although many corticosteroids are available today, there is still a need for highly potent compounds with minimal adverse effects. Methylprednisolone aceponate (MPA) has recently been synthesized.
A, Kecskés +4 more
openaire +2 more sources
Journal of the European Academy of Dermatology and Venereology, 2011
AbstractAlthough emollients can be sufficient to manage mild atopic dermatitis (AD), acute flares resulting in moderate‐to‐severe symptoms require treatment with anti‐inflammatory agents, such as topical corticosteroids (TCs) and topical calcineurin inhibitors (TCIs).
openaire +2 more sources
AbstractAlthough emollients can be sufficient to manage mild atopic dermatitis (AD), acute flares resulting in moderate‐to‐severe symptoms require treatment with anti‐inflammatory agents, such as topical corticosteroids (TCs) and topical calcineurin inhibitors (TCIs).
openaire +2 more sources
Skin Pharmacology, 2009
Background: Topical corticoids decrease de novo collagen synthesis in the human skin. Objective: We studied the effect of three corticoids, hydrocortisone (HC), methylprednisolone aceponate (MPA) and momethasone furoate (MMF) on the de novo synthesis of type I and III collagens.
K M, Haapasaari +3 more
openaire +2 more sources
Background: Topical corticoids decrease de novo collagen synthesis in the human skin. Objective: We studied the effect of three corticoids, hydrocortisone (HC), methylprednisolone aceponate (MPA) and momethasone furoate (MMF) on the de novo synthesis of type I and III collagens.
K M, Haapasaari +3 more
openaire +2 more sources
Journal of Pharmaceutical Innovation
PurposeAtopic dermatitis (AD) is a chronic, recurrent inflammatory skin disorder frequently observed in infants, where safe and effective therapies remain a clinical challenge. Methylprednisolone aceponate (MPA), a fourth-generation corticosteroid, is widely preferred due to its favorable risk-benefit profile and pediatric approval from four months of ...
YÜCEL, ÇİĞDEM +3 more
openaire +2 more sources
PurposeAtopic dermatitis (AD) is a chronic, recurrent inflammatory skin disorder frequently observed in infants, where safe and effective therapies remain a clinical challenge. Methylprednisolone aceponate (MPA), a fourth-generation corticosteroid, is widely preferred due to its favorable risk-benefit profile and pediatric approval from four months of ...
YÜCEL, ÇİĞDEM +3 more
openaire +2 more sources
Experimental Dermatology, 2007
Abstract: Although introduced more than 50 years ago, topical glucocorticoids are still the first line therapy for many inflammatory skin disorders such as atopic eczema, contact dermatitis and many others. Recently, significant improvements have been made to optimize the ratio of desired to unwanted effects.
Parham, Mirshahpanah +6 more
openaire +2 more sources
Abstract: Although introduced more than 50 years ago, topical glucocorticoids are still the first line therapy for many inflammatory skin disorders such as atopic eczema, contact dermatitis and many others. Recently, significant improvements have been made to optimize the ratio of desired to unwanted effects.
Parham, Mirshahpanah +6 more
openaire +2 more sources